NZX & Media Release. Link here. 1 October 2014 SeaDragon strengthens leadership team to transition to Omega 3 production Permanent marketing, sales and finance appointments reflect SeaDragon growth and strong prospects New Zealand’s largest refiner and blender of high-quality fish oils SeaDragon today announced it has expanded its leadership team with the appointment of a permanent […]
DUBLIN, Ireland, MELBOURNE, Australia–‐ September 18, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-09-18 18:08:452018-01-06 18:09:19Nexvet – Two industry leaders join the Board of Directors
15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-09-15 18:09:292018-01-06 18:10:02Nexvet expands veterinary biologics research team
19 August 2014. Link here. The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday: 1. That Dr. Doug Wilson, retiring from office as Director of SeaDragon Limited by rotation, is re-elected as a Director of SeaDragon Limited; 2. That Mr. Jeremy Curnock Cook, retiring from office as Director of SeaDragon […]
Outstanding capital return in final distribution for Australian Bioscience Fund I Australia’s best performing biotech fund in recent years as per Cambridge Associates ratings 13 August 2014: AusBiotech Industry Spotlight here. Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-08-13 18:17:012018-01-06 18:17:22BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors
11 August 2014. Link here. Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces that its Auckland-based subsidiary Rex Bionics Ltd (RBL) has been awarded substantial new grant funding by the New Zealand Government to support the research and development of REX 3, the platform […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-08-11 18:17:272018-01-06 18:17:46Rex Bionics awarded major research & development grant by NZ Government
NZX – market Information 7 August 2014. Link here. Edison Investment Research Releases SeaDragon Update Edison Investment Research has released a SeaDragon Corporate outlook that can be found attached to this release and also available on our website. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336 About SeaDragon: www.seadragon.co.nz SeaDragon (NZX:SEA) is Australasia’s […]
5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Maiden Interim Results for the six months ended 31 May 2014 5 August 2014, Rex Bionics Plc (RXB) (formerly Union MedTech Plc) the AIM-listed developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces its maiden unaudited results for […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-08-05 18:13:262018-01-06 18:14:02Rex Bionics: Interim Results for six months ended 31 May 2014
Released 5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Appointment of Crispin Simon as Chief Executive Officer Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces the appointment of Crispin Simon as Chief Executive Officer. Crispin, who has a 25-year […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-08-05 18:12:422018-01-06 18:13:16Rex Bionics: Appointment of Crispin Simon as CEO
Link here. 28 July 2014. SeaDragon Limited appoints Patrick Geals as a Non-Executive Independent Director SeaDragon Limited (SeaDragon), Australasia’s largest refiner and blender of high-quality internationally certified concentrated fish oils and fractions has appointed pharmaceutical and food industry expert Patrick Geals as a Non-Executive Independent Director. Welcoming Mr. Geals to the board, SeaDragon Chairman Dr. Doug […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-07-28 18:09:132018-01-06 18:09:34SeaDragon Appoints Independent Director – Patrick Geals
SeaDragon strengthens leadership team
/in Portfolio Companies, SeaDragonNZX & Media Release. Link here. 1 October 2014 SeaDragon strengthens leadership team to transition to Omega 3 production Permanent marketing, sales and finance appointments reflect SeaDragon growth and strong prospects New Zealand’s largest refiner and blender of high-quality fish oils SeaDragon today announced it has expanded its leadership team with the appointment of a permanent […]
Nexvet – Two industry leaders join the Board of Directors
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, MELBOURNE, Australia–‐ September 18, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the […]
Nexvet expands veterinary biologics research team
/in Pharmamark, Portfolio Companies15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]
SeaDragon 2014 Annual Meeting Results and Determinations
/in Portfolio Companies, SeaDragon19 August 2014. Link here. The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday: 1. That Dr. Doug Wilson, retiring from office as Director of SeaDragon Limited by rotation, is re-elected as a Director of SeaDragon Limited; 2. That Mr. Jeremy Curnock Cook, retiring from office as Director of SeaDragon […]
BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors
/in BioSciences ManagersOutstanding capital return in final distribution for Australian Bioscience Fund I Australia’s best performing biotech fund in recent years as per Cambridge Associates ratings 13 August 2014: AusBiotech Industry Spotlight here. Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% […]
Rex Bionics awarded major research & development grant by NZ Government
/in Portfolio Companies, Rex Bionics11 August 2014. Link here. Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces that its Auckland-based subsidiary Rex Bionics Ltd (RBL) has been awarded substantial new grant funding by the New Zealand Government to support the research and development of REX 3, the platform […]
SeaDragon Update: Edison Investment Research Releases SeaDragon Update
/in Portfolio Companies, SeaDragonNZX – market Information 7 August 2014. Link here. Edison Investment Research Releases SeaDragon Update Edison Investment Research has released a SeaDragon Corporate outlook that can be found attached to this release and also available on our website. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336 About SeaDragon: www.seadragon.co.nz SeaDragon (NZX:SEA) is Australasia’s […]
Rex Bionics: Interim Results for six months ended 31 May 2014
/in Portfolio Companies, Rex Bionics5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Maiden Interim Results for the six months ended 31 May 2014 5 August 2014, Rex Bionics Plc (RXB) (formerly Union MedTech Plc) the AIM-listed developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces its maiden unaudited results for […]
Rex Bionics: Appointment of Crispin Simon as CEO
/in Portfolio Companies, Rex BionicsReleased 5 August 2014. Link here. Rex Bionics Plc (“Rex Bionics” or the “Company”) Appointment of Crispin Simon as Chief Executive Officer Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use by wheelchair users, today announces the appointment of Crispin Simon as Chief Executive Officer. Crispin, who has a 25-year […]
SeaDragon Appoints Independent Director – Patrick Geals
/in Portfolio Companies, SeaDragonLink here. 28 July 2014. SeaDragon Limited appoints Patrick Geals as a Non-Executive Independent Director SeaDragon Limited (SeaDragon), Australasia’s largest refiner and blender of high-quality internationally certified concentrated fish oils and fractions has appointed pharmaceutical and food industry expert Patrick Geals as a Non-Executive Independent Director. Welcoming Mr. Geals to the board, SeaDragon Chairman Dr. Doug […]